2nd Quarter - Report

VAN HEUVELEN STRATEGIES, LLC for ALLERGAN PLC (FORMERLY KNOWN AS ACTAVIS)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$40,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 21, 2014 $40,000 Replaced
2nd Quarter - Amendment Oct 14, 2014 $50,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Prescription drug user fee act and other issues related to generic drugs; H.R. 3204 - The Drug Quality and Security Act, S. 1720 - Patent Transparency and Improvements Act of 2013, H.R. 3309 - Innovation Act, S. 2049 - Transparency in Assertion of Patents Act, S. 1013 - Patent Abuse Reduction Act, S. 1612 - Patent litigation and Integrity Act, H.R. 325 - Continuing Resolution, S. Con. Res. 8, FY 2014 Budget Resolution.on and Integrity Act.

LobbyistCovered position, as disclosed
ROBERT VAN HEUVELEN Chief of Staff to Senator Kent Conrad
STEPHEN DOUGLAS WARD Chief of Staff to Senator Jeff Bingaman

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1612 (113th), H.R. 3204 (113th), H.R. 3309 (113th), S.Con.Res. 8 (113th), S. 2049 (113th), H.R. 325 (113th), S. 1720 (113th), S. 1013 (113th)

Budget/Appropriations BUD

Prescription drug user fee act and other issues related to generic drugs; H.R. 3204 - The Drug Quality and Security Act, S. 1720 - Patent Transparency and Improvements Act of 2013, H.R. 3309 - Innovation Act, S. 2049 - Transparency in Assertion of Patents Act, S. 1013 - Patent Abuse Reduction Act, S. 1612 - Patent litigation and Integrity Act, H.R. 325 - Continuing Resolution, S. Con. Res. 8, FY 2014 Budget Resolution.

LobbyistCovered position, as disclosed
ROBERT VAN HEUVELEN Chief of Staff to Senator Kent Conrad
STEPHEN DOUGLAS WARD Chief of Staff to Senator Jeff Bingaman

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1612 (113th), H.R. 325 (113th), H.R. 3204 (113th), S.Con.Res. 8 (113th), S. 1013 (113th), S. 1720 (113th), H.R. 3309 (113th), S. 2049 (113th)

Labor Issues/Antitrust/Workplace LBR

Prescription drug user fee act and other issues related to generic drugs; H.R. 3204 - The Drug Quality and Security Act, S. 1720 - Patent Transparency and Improvements Act of 2013, H.R. 3309 - Innovation Act, S. 2049 - Transparency in Assertion of Patents Act, S. 1013 - Patent Abuse Reduction Act, S. 1612 - Patent litigation and Integrity Act, H.R. 325 - Continuing Resolution, S. Con. Res. 8, FY 2014 Budget Resolution.

LobbyistCovered position, as disclosed
ROBERT VAN HEUVELEN Chief of Staff to Senator Kent Conrad
STEPHEN DOUGLAS WARD Chief of Staff to Senator Jeff Bingaman

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1720 (113th), S. 2049 (113th), S. 1612 (113th), H.R. 325 (113th), S. 1013 (113th), H.R. 3309 (113th), S.Con.Res. 8 (113th), H.R. 3204 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.